Evidence map›Paper›PMID 34513878›Full record

ArticleFrontiers in medicine2021

Real-Life Experience With First-Line Therapy Bortezomib Plus Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stem-Cell Transplantation.

Gabriele Buda, Maria Livia Del Giudice, Elisabetta Antonioli, Francesco Ghio, Enrico Orciuolo, Riccardo Morganti, Francesca Martini, Michela Staderini, Sara Galimberti, Mario Petrini

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Gabriele BudaDepartment of Experimental and Clinical Medicine, UO Hematology, AOUP University of Pisa, Pisa, Italy.
Maria Livia Del GiudiceDepartment of Experimental and Clinical Medicine, UO Hematology, AOUP University of Pisa, Pisa, Italy.
Elisabetta AntonioliCareggi University Hospital, Florence, Italy.
Francesco GhioDepartment of Experimental and Clinical Medicine, UO Hematology, AOUP University of Pisa, Pisa, Italy.
Enrico OrciuoloDepartment of Experimental and Clinical Medicine, UO Hematology, AOUP University of Pisa, Pisa, Italy.
Riccardo MorgantiPisana University Hospital, Pisa, Italy.
Francesca MartiniDepartment of Experimental and Clinical Medicine, UO Hematology, AOUP University of Pisa, Pisa, Italy.
Michela StaderiniCareggi University Hospital, Florence, Italy.
Sara GalimbertiDepartment of Experimental and Clinical Medicine, UO Hematology, AOUP University of Pisa, Pisa, Italy.
Mario PetriniDepartment of Experimental and Clinical Medicine, UO Hematology, AOUP University of Pisa, Pisa, Italy.
University of Pisa · ITAzienda Ospedaliero-Universitaria Careggi · ITAzienda Ospedaliera Universitaria Pisana · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

bortezomibchemotherapychemotherapy resistancemelphalanmyeloma

Identifiers

PMID34513878
PMCPMC8429780
OpenAlexW3198416203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.